Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

Université de Montréal

$726,750.00

Cardioprotective effect of a cyclic azapeptide ligand of CD36 against ischemia-reperfusion damage and dysfunction in mice

EF 2021-22

Résumé
Every 7 minutes, an individual dies from a heart attack. In many instances, what happens is that the blood vessels bringing blood and nutrients to the heart are blocked. Blood flow should be restored very rapidly for the heart cells to survive and limit the dead zone. However, unexpectedly, when the flow is restored, it may also increase the damage to the heart. Another phenomenon takes place during restoration of blood flow. Indeed, the blood contains cells that are going into the heart to clear up debris of dead cells. This is important because we could enhance the properties of these cells to clear up debris and be beneficial for the heart. So in this proposal, we will investigate the potential of new drugs to prevent myocardial dysfunction when the heart lacks nutrients and oxygen, and at the same time help for healing. Our project is unique as we are the only group who have designed, characterized and patented these novel drugs. As of yet, an important number of therapeutic avenues have been explored but few led to positive results in the clinic. However, none of these drugs targeted both the heart and blood cells, thus clearing dead cells and debris of the injured heart. We believe that our work suggest a novel therapeutic avenues which may surpass what is available in terms of efficacy. Although the proposed studies are mainly focused on an understanding of drug action and to demonstrate their beneficial effect in animal models of the disease, the knowledge to be gained is mandatory to better position the drugs for their future development by pharma. Accordingly, we believe that this work may be the basis to new drugs available for heart disease.
Programme
Project Grant
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
444385
Name
Marleau Sylvie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Cardiovascular System - B: Heart and Circulation
Projecttitle
Cardioprotective effect of a cyclic azapeptide ligand of CD36 against ischemia-reperfusion damage and dysfunction in mice
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$726,750
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Azapeptides; Cardiomyocyte; Cardioprotection; Cd36 Receptor; Macrophage; Myocardial Ischemia-Reperfusion
Abstract
Every 7 minutes, an individual dies from a heart attack. In many instances, what happens is that the blood vessels bringing blood and nutrients to the heart are blocked. Blood flow should be restored very rapidly for the heart cells to survive and limit the dead zone. However, unexpectedly, when the flow is restored, it may also increase the damage to the heart. Another phenomenon takes place during restoration of blood flow. Indeed, the blood contains cells that are going into the heart to clear up debris of dead cells. This is important because we could enhance the properties of these cells to clear up debris and be beneficial for the heart. So in this proposal, we will investigate the potential of new drugs to prevent myocardial dysfunction when the heart lacks nutrients and oxygen, and at the same time help for healing. Our project is unique as we are the only group who have designed, characterized and patented these novel drugs. As of yet, an important number of therapeutic avenues have been explored but few led to positive results in the clinic. However, none of these drugs targeted both the heart and blood cells, thus clearing dead cells and debris of the injured heart. We believe that our work suggest a novel therapeutic avenues which may surpass what is available in terms of efficacy. Although the proposed studies are mainly focused on an understanding of drug action and to demonstrate their beneficial effect in animal models of the disease, the knowledge to be gained is mandatory to better position the drugs for their future development by pharma. Accordingly, we believe that this work may be the basis to new drugs available for heart disease.
Competitiondate
202104
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Marleau, Sylvie
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $726,750~ $0~